Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Recruiting now · Phase 3

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Key facts

Study ID

NCT07555938

Run by

Hoffmann-La Roche

People needed

380

Starts

2026-06-23

Expected to finish

2033-01-31

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.
• Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
• MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
• Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide
• Participants must have measurable disease during screening

You may not qualify if…

• Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
• Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells
• GI disease that might significantly alter absorption of oral drugs
• Participants must not have any ongoing CNS disease or non-secretory myeloma

Where it is running

• City of Hope National Medical Center — Duarte, California, United States (enrolling)
• City of Hope - Lennar Foundation Cancer Center — Irvine, California, United States (enrolling)
• Emory University Hospital Midtown — Atlanta, Georgia, United States (enrolling)
• Novant Health Cancer Institute — Charlotte, North Carolina, United States (enrolling)
• Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists — Winston-Salem, North Carolina, United States (enrolling)
• TriHealth Cancer and Blood Institute — Cincinnati, Ohio, United States (enrolling)
• Nagoya City University Hospital — Aichi, Japan (enrolling)
• University Hospital Kyoto Prefectural University of Medicine — Kyoto, Japan (enrolling)
• The Cancer Institute Hospital of JFCR — Tokyo, Japan (enrolling)
• Yamagata University Hospital — Yamagata, Japan (enrolling)
• Auxilio Mutuo Cancer Center — San Juan, Puerto Rico (enrolling)
• Chonnam National University Hwasun Hospital — Jeollanam-do, South Korea (enrolling)
• Seoul National University Hospital — Seoul, South Korea (enrolling)
• Asan Medical Center — Seoul, South Korea (enrolling)
• Seoul St Mary's Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.